News and Trends 4 Apr 2023
Alzamend pushing ahead with Alzheimer’s vaccine trial
Alzamend Neuro, Inc. has announced the initiation of a phase I/IIA clinical trial for its immunotherapy vaccine (ALZN002) to treat mild to moderate dementia of the Alzheimer’s type. The purpose…